Premier Alternatives

TRIANA Biomedicines

Discovery Tools (Healthcare) · Lexington, MA · Founded 2019 · Privately Held (backing)

Operator of a pharmaceutical company intended to discover and develop molecular glues. TRIANA Biomedicines is based in Lexington, MA and was founded in 2019. It was valued at $258 million at its later-stage round in Nov 2025, the last priced event on record. It has raised $246 million across 2 recorded rounds; the latest was a $120 million Series B in Nov 2025.

PMV mark · valuation
$258.0M
Oct 2026
Priced at
its later-stage round
Nov 2025
Total raised
$246.1M
Last round
Later Stage VC (Series B)
Nov 2025

TRIANA Biomedicines key facts

as of Oct 2026
  • Operator of a pharmaceutical company intended to discover and develop molecular glues.
  • TRIANA Biomedicines is valued at approximately $258.0M as of Oct 2026, set at its later-stage round, Nov 2025; nothing has traded since, per PrivateMarketView’s mark.
  • It has raised $246.1M across 2 recorded rounds; the latest was Later Stage VC (Series B) ($120.1M) in Nov 2025.
  • Notable investors include Lightspeed Venture Partners, Bessemer Venture Partners, RA Capital Management, The Invus Group, Pfizer Ventures — 12 tracked in total.
  • TRIANA Biomedicines has filed 3 Form Ds with the SEC since 2022, most recently Dec 2025 ($120.1M sold to 20 investors).
  • Status: Privately Held (backing).
PrivateMarketView mark
MEDIUM confidence
$258.0M

Valued at $258.0M at its later-stage round, Nov 2025. Nothing has traded since.

set by its last priced roundas of Oct 2026question about this number?
Free account
More of TRIANA Biomedicines with a free account
  • ·The complete investor list: 12 names
  • ·Everyone on the team, board and advisors included
  • ·Watch TRIANA Biomedicines: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

TRIANA Biomedicines funding rounds

2 rounds
Nov 2025Later Stage VC (Series B)$120.1M▮
Apr 2022Early Stage VC (Series A)$110.0M▮
Full funding history →

TRIANA Biomedicines leadership

TRIANA Biomedicines valuation

TRIANA Biomedicines was valued at $258 million at its later-stage round in Nov 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.

How much has TRIANA Biomedicines raised?

TRIANA Biomedicines has raised $246 million across 2 recorded rounds since 2022. The largest was a $120 million Series B in Nov 2025.

TRIANA Biomedicines has filed 3 Form Ds with the SEC since 2022, most recently in Dec 2025 ($120 million sold to 20 investors).

TRIANA Biomedicines investors

12 investors are on record for TRIANA Biomedicines, including Lightspeed Venture Partners, Bessemer Venture Partners, RA Capital Management and The Invus Group. The Series B in Nov 2025 drew 10 investors.

Who runs TRIANA Biomedicines

19 people are listed on the TRIANA Biomedicines team: 6 executives, 12 board members and 1 advisor or observer, including Mohan Bala (Chief Operating Officer) and Fatou Ndiaye (Vice President). 17 of them have a verified direct contact on file.

Comparable companies

Comparable discovery tools (healthcare) names by valuation on PrivateMarketView: Scipher Medicine ($496 million), Outpace Bio ($220 million) and Nature's Toolbox ($71 million).

About TRIANA Biomedicines

Operator of a pharmaceutical company intended to discover and develop molecular glues. The company leverages technology to stabilize pre-existing or create de novo interactions between multiple proteins and alter the fate or functionality of the disease target, enabling healthcare professionals to develop products for a wide range of therapeutic applications.

Industry
Discovery Tools (Healthcare)
Sector
Healthcare
HQ
Lexington, MA, United States
Founded
2019
Employees
50
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.